Merit Med Sys Inc SEC Filings

Merit Medical Systems (MMSI) announced a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The total purchase consideration is $22 million, including $19 million cash at closing and up to $3 million in contingent payments tied to milestones.

The closing is expected in Q4 2025, subject to satisfaction or waiver of customary closing conditions. Merit referenced non-GAAP measures in its press release and stated that a quantitative reconciliation to GAAP is not available without unreasonable effort.

Martha Goldberg Aronson, President and CEO and a director of Merit Medical Systems, Inc. (MMSI), reported an amended Form 4 showing a grant of 19,594 restricted stock units (RSUs) on 10/03/2025. The RSUs carry no cash purchase price and vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to her continued service; each RSU converts to one share of common stock upon vesting. The Form 4/A was signed by an attorney-in-fact on 10/07/2025.

Martha Goldberg Aronson, President and CEO of Merit Medical Systems, Inc. (MMSI), received a grant of 19,594 restricted stock units (RSUs) on 10/03/2025. The RSUs were granted at a reported price of $0 and represent the contingent right to receive one share of common stock per RSU upon vesting. The award vests in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service. After the grant, the reporting person is shown as beneficially owning 19,594 shares directly. The Form 4 was submitted via attorney-in-fact on 10/07/2025.

Aronson Martha Goldberg filed an Initial Statement of Beneficial Ownership (Form 3) for Merit Medical Systems Inc. The filing lists her address in South Jordan, UT and identifies her role as President and CEO. The date of the event requiring the statement is 10/03/2025.

The filing discloses no securities beneficially owned by the reporting person at the time of this Form 3. The document was signed by an attorney-in-fact, Brian G. Lloyd, on 10/07/2025.

Merit Medical Systems insider transactions: The company's President and CEO, Fred P. Lampropoulos, reported multiple stock option exercises and share surrenders on 08/29/2025. He exercised 159,151 options at a $55.73 exercise price and an additional 2,000 options at $55.73, resulting in 159,151 and 2,000 underlying shares respectively that were reported as acquired. He also surrendered 124,824 shares (for payroll taxes and option payment) and his spouse surrendered 1,454 shares for the same purpose; neither surrender involved open-market sales. Post-transactions, Mr. Lampropoulos beneficially owned 1,204,779 shares directly and certain additional shares indirectly through spouse and 401(k) holdings. Several outstanding option grants with various exercise prices and vesting schedules remain.

Lynne N. Ward, a director of Merit Medical Systems, Inc. (MMSI), executed option exercises and share sales on 08/22/2025. She exercised 3,000 non-qualified stock options with a $34.46 exercise price, resulting in 3,000 shares acquired. The same day she sold 3,000 shares in multiple transactions at a weighted average price of $88.56. After these transactions she beneficially owned 12,809 shares. The exercised options were originally granted with a $34.46 strike and become exercisable in equal annual installments of 33% commencing 08/28/2020; the exercised tranche had an expiration date of 08/28/2026.